WinstonWınston
The Cooper Companies logo

The Cooper Companies

COO
47
Medical - Instruments & Supplies · Healthcare
Price
$71.71
-1.39 (-1.90%)
Market Cap
$13.99B
Exchange
NASDAQ
Winston Score
47
Winston is serious
Mixed quality — meaningful strengths and weaknesses.

The Cooper Companies, Inc., together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment offers spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, myopia, ocular dryness and eye fatigues in the Americas, Europe, Middle East, Africa, and Asia

Winston Score History

Politician Trades

8 trades / 12mo

3 Congressional buys and 5 sells on COO in the last 12 months.

Unlock the full Smart Money Map — every trade plotted on the price chart with politicians, amounts and returns since each trade. Founder's Deal is $57/mo locked for life.

Unlock politician trades

Growth Profile

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+6.2% YoY

YoY Growth Rate

Slow revenue growth

EPS Growth

+26.9% YoY

YoY Growth Rate

EPS growth accelerating

R&D Spend

$172M/ year

Rising (+11% vs prior year)

4.2% of revenue

Below sector average (18%)

R&D investment increasing — building for the future

Insider Activity

0.7%ownership

Flat

Insiders holding steady — not selling despite ability to

Cash Position

Cash flow positive

$125M cash & investments

Quarterly Free Cash Flow

↑ Burn rate improving

Company generates more cash than it spends — no dilution risk from fundraising

Growth context

The Cooper Companies is growing revenue at 6% year-over-year. The Winston Score measures business quality today — these growth metrics show what could matter tomorrow.

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Share count broadly stable

+0.3% over 4y

The share count has stayed roughly flat over this period — little dilution or buyback activity.

Diluted shares outstanding: 199.4M (2021) → 200.0M (2025)

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin
67.9%
Premium pricing power — 67.9% gross margin
Operating Margin
20.8%
Excellent — 20.8% operating margin
ROCE
2.0%
Weak — 2.0% return on capital

ROIC between 0% and 5%. They earn a few cents back per dollar invested in the business.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY
+5.7%
Slow sales growth (5.7% YoY)
EPS YoY
-3.4%
Earnings shrinking (-3.4% YoY)

Slight earnings drop. Typical near a cyclical low.

EPS Consistency
2/8 quarters
Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion
216%
Turns 216% of profit into real cash
FCF Margin
11.8%
Modest free cash flow (11.8%)

FCF margin between 10% and 20%. Every $100 in sales becomes $10 to $20 in real cash.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity
0.30
Conservative — low debt load (0.30)
Interest Cover
6.76x
Adequate interest coverage (6.8x)

Interest coverage between 3 and 8. Profits cover interest several times over.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)
35.5x
Pricey — P/E 35.5

P/E over 35. The market is pricing in heavy, sustained growth.

P/E vs Forward
+21.8
GROWING
Earnings expected to grow meaningfully — cheaper on forward P/E (35.5 → 13.8)

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.
🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.
Start free trial